Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Receives Average Rating of “Hold” from Brokerages
Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $24.73.
Several equities research analysts recently commented on AMPH shares. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. TheStreet cut shares of Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, November 7th. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, November 20th. Finally, ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday.
In other Amphastar Pharmaceuticals news, SVP Yakob Liawatidewi sold 1,515 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $21.24, for a total transaction of $32,178.60. Following the transaction, the senior vice president now owns 36,670 shares of the company’s stock, valued at approximately $778,870.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jack Y. Zhang sold 300,000 shares of the company’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $20.82, for a total value of $6,246,000.00. Following the completion of the transaction, the chief executive officer now owns 2,147,316 shares in the company, valued at approximately $44,707,119.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 323,155 shares of company stock valued at $6,742,840. Company insiders own 30.80% of the company’s stock.
NASDAQ AMPH traded down $0.01 on Tuesday, hitting $19.03. 948,296 shares of the company were exchanged, compared to its average volume of 202,216. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.11 and a quick ratio of 1.84. Amphastar Pharmaceuticals has a twelve month low of $16.71 and a twelve month high of $25.43. The firm has a market capitalization of $915.76 million, a P/E ratio of 90.62 and a beta of 1.16. The company’s 50 day moving average price is $19.02 and its 200-day moving average price is $20.24.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, November 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. The company had revenue of $80.14 million during the quarter, compared to analysts’ expectations of $78.53 million. Amphastar Pharmaceuticals had a net margin of 15.77% and a return on equity of 5.07%. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period last year, the company posted $0.12 earnings per share. As a group, equities analysts expect that Amphastar Pharmaceuticals will post 0.05 EPS for the current year.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
Further Reading: Benefits of owning preferred stock
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.